Ube Industries, Inc.

Ube Corporation

Sayaka Ogi

Yasuhiro Aga

Tomio Kimura

Shigeru Ushiyama

Noriaki Iwase

Shigeyuki Kono

Hidetoshi Sunamoto

Yusuke Shiraishi

Masahiro Kojima

Takashi Matsushita

Masayuki Tanaka

Yukinori Wada

Satoshi Umezaki

Kazuhiro Onuma

Makoto Okudo

Masaaki Matoyama

Akishi Ninomiya

Hiroyoshi Kawada

Hayato Nishiyama

A pharmaceutical composition including a compound represented by the formula (I) or a pharmacologically acceptable salt thereof wherein two R moieties each independently are a Calkyl group or are groups bonded to each other to form a Calkylene group; A is an optionally substituted Caryl group or an optionally substituted heteroaryl group; and R, Rand Reach independently are an optionally substituted linear or branched Calkyl group, wherein the pharmaceutical composition is administered in combination with an immunotherapeutic agent. 

Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent

The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a Calkyl group or the like; and R, Rand Reach independently represent an optionally substituted linear or branched Calkyl group. 

Substituted dihydropyrrolopyrazole derivative

Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein Lis an optionally substituted Calkylene group or the like, Lis a single bond or the like, Lis a single bond or the like, R, R, and Rare each independently an optionally substituted Calkyl group or the like, Ris a hydrogen atom or the like, and Ris a hydrogen atom or the like.

Substituted dihydropyrrolopyrazole compound

Growing community of inventors

Ube, Japan

Sayaka Ogi